Back to top
more

Omnicell (OMCL)

(Real Time Quote from BATS)

$42.55 USD

42.55
25,856

+0.16 (0.38%)

Updated Oct 7, 2024 10:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 252)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Medical Info Systems Stock Outlook: Short-Term Pain to Stay

The ongoing digital transition is accelerating demand for IT service solutions in healthcare despite legal and regulatory hurdles.

    Why Is Omnicell (OMCL) Up 2.6% Since Its Last Earnings Report?

    Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1

      Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

        Omnicell (OMCL) Down 12.7% Since Earnings Report: Can It Rebound?

        Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Here's Why You Should Keep Omnicell (OMCL) in Your Portfolio

          Omnicell (OMCL) continues to progress well with its three-legged strategy. However, escalating costs and tough hospital spending trends pose threats.

            Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4

            Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.

              Omnicell's Rising Costs Affect Bottom Line Amid Competition

              Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.

                Why Is Omnicell (OMCL) Down 5% Since the Last Earnings Report?

                Omnicell (OMCL) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Omnicell's Higher Investments Drive Costs, Competition Rife

                  Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.

                    Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3

                    Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.

                      Omnicell (OMCL) Gains on Product Launches, Global Expansion

                      The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.

                        Omnicell (OMCL) Gains on Product Launches, Competition Rife

                        Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.

                          Omnicell Upgrades Web Portal, Grows in Medication Management

                          Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

                            Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2

                            Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.

                              Omnicell (OMCL) Catches Eye: Stock Moves 13.5% Higher

                              Omnicell, Inc. (OMCL) moved big last session, as its shares jumped over 13% on the day.

                                Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition

                                On Jul 4, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).

                                  Why Is Omnicell (OMCL) Up 3.3% Since the Last Earnings Report?

                                  Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag

                                    Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.

                                      Omnicell's Aesynt Buyout Looks Promising amid Several Woes

                                      On Apr 6, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).

                                        Why Is Omnicell (OMCL) Up 3% Since the Last Earnings Report?

                                        Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                          Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise

                                          On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).

                                            Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss

                                            Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.

                                              Omnicell Partners with DCH Health for Sterile Compounding

                                              Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.

                                                Omnicell Unveils XT Series Automated Dispensing System

                                                Omnicell, Inc. (OMCL) recently introduced a new generation of medication and supply automation that is fully integrated with the company's Unity enterprise platform -- XT series.

                                                  Omnicell to Buy Ateb, Expand in Adherence Tools Market

                                                  Omnicell, Inc. (OMCL) recently inked a deal to buy pharmacy-based patient care solution provider Ateb, Inc and its Canadian affiliate, Ateb Canada Ltd.